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S340 Poster Session IIproduce large amounts of interferon-gamma (IFN-g) under inflam-
matory conditions. Here we address the role of IFN-g production by
Tregs in the course of experimental GvHD.
Methods: In a C57BL/6 into BALB/c mouse model of acute GvHD
we monitored the intracellular cytokine expression of Tregs using
FoxP3-reporter mice (C56BL/6) and congenic markers. We ad-
dressed the role of IFN-g in experimental GvHD i) by employing
the IFN-g blocking mAb XMG1.2 and ii) by adoptive transfer of
Tregs and/ or effector T cells purified from ifng–/– mice. GvHD
severity was monitored by survival, clinical score and histological
analysis.
Results: Co-transferred Tregs in a C57BL/6 into BALB/c model
readily secreted IFN-g but stably remained FoxP3+ and prevented
lethal GvHD. Intracellular staining revealed that at day 4 after trans-
plantation approximately 35% of these allogeneic Tregs produced
IFN-g. In this experimental setting blocking of IFN-g with mAb
completely abolished the protective effect of Tregs and led to early
death from exacerbated GvHD. Of note, we also observed a similar
fatal outcome of experimental GvHD when we co-transferred
ifng–/– Tregs and wild type effector T cells.
Conclusions: Our data suggest that IFN-g should not be regarded
as an adverse pro-inflammatory cytokine under the highly inflamma-
tory environment of acute GvHD since it is required for the protec-
tive action of Tregs. We hypothesize that this may be due to
a deviation of effector T cell profiles towards Th17. In ongoing
experiments we therefore address this issue by employing effector
T cells from il17a–/– / il17f–/– double knock-out mice.522
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Objective: The graft-versus-leukemia (GVL) effect of donor-lym-
phocyte infusions (DLI) is well documented in hematologic malig-
nancies, including multiple myeloma (MM). We evaluated the role
of DLI in persistent or recurrent MM after allogeneic hematopoietic
stem cell transplantation (allo HCT).
Materials and Methods: We identified 23 patients with MM, who
received DLI at UT-MD Anderson Cancer Center between 7/1996
-6/2008. Patients had persistent or recurrent disease after allo HCT,
and were treated with DLI collected from their original allo HCT
donors.
Results: Nineteen patients received DLI from matched related do-
nors (MRD) and 4 from matched unrelated donors (MUD). Median
age at DLI was 51 years (range: 38-62). A total of 33 DLI doses were
administered. Seventeen patients received 1 infusion, 4 patients re-
ceived 2, and 2 patient received 4 infusions. Median interval between
allo HCT and the first DLI was 8.2 months (range: 2.9 to 119.5).
Median follow up from the first DLI was 18 months (range 1-126).
Twenty-six DLI (78%) were given without preceding cytoreductive
chemotherapy. The median DLI dose was 3.5 x 107 CD3+ T cells
(range 0.5 to 14.8 x 107). Overall response rate was 30%, with 10
of 33 DLI doses associated with objective clinical responses (3 CR,
5 VGPR, 2 PR). Thirteen (39%) additional DLI were followed by
stable disease. Median response duration was 5 months (range 2-
10). ORR to DLI in relapsed disease was 10% (2/20), compared to
61% (8/13) for residual disease (p 5 0.0048). Grade II-IV acute
graft-versus-host disease (GVHD) was seen in 6 (26%) patients,
with median onset of 5 weeks fromDLI. None of the patients devel-
oped chronic GVHD after DLI. Median overall survival from the
first DLI was 18.6 months.
Conclusions: DLI is associated with objective clinical responses
patients with relapsed or persistent MM, with a significantly higher
response rate in patients with persistent vs. relapsed disease. The risk
of acute GVHD was low. The role of DLI needs to be furtherexplored in prospective clinical trials for patients with relapsed or
persistent MM.523
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It is known that Graft-vs-Host Disease (GVHD) occurs in
response to minor histocompatibility antigens, but little is known
about the kinetics of donor T cell proliferation and homing in minor
mismatch models of allogeneic hematopoietic cell transplantation
(HCT). This is in contrast tomodels across major histocompatibility
barriers, where early development of GVHDhas been better charac-
terized. Yet, because minor mismatch models are more similar to
clinical HCT, it is critical to understand how GVHD develops
across minor barriers. To investigate temporal and spatial events
of donor T cell activation and homing, side-by-side transplants
were conducted using bone marrow and enriched CD4 and CD8
T cells (Tcon) from donor C56BL/6 mice (H2b) into either major
mismatched Balb/c (H2d), or minor mismatched Balb.b (H2b), irra-
diated recipients. Balb/c mice received 1x106 Tcon while Balb.b
mice received 15x106 Tcon, based on titration experiments. Prolifer-
ation and migration of donor Tcon was monitored using in vivo and
ex vivo bioluminescent imaging, and CFSE labeling. Expression of
T cell activation and homing markers was examined using flow cy-
tometry analysis of donor CD4 andCD8 cells re-isolated from trans-
planted mice. Donor Tcon from Balb.b mice exhibited significantly
reduced proliferation at both 3 and 6 days post transplant (p\0.01, n
5 43). But, mirroring our earlier findings inmajormismatchmodels,
donor Tcon in the minor model homed to nodal sites by day 3, fol-
lowed by an exit to tissues by day 6, albeit reduced. No significant
differences in the expression of the activation and homing markers
examined were noted by day 3, although there was variation across
tissues and between CD4 and CD8 cells. By day 6, donor T cells
re-isolated from Balb.b recipients had reduced levels of a4b7 and
P-selectin, and increased retention of CD62L. These data support
the idea that early events of donor T cell activation, particularly spa-
tially, are similar across minor and major histocompatiblity barriers,
reinforcing the usefulness of both models as translational research
tools. More importantly, these data suggest that delays in visible
GVHD onset in minor mismatch tranpslants arise from temporal
differences in the effector phase of T cell action, rather than delays
in the initiation phase. These findings support targeting very early
events in T cell activation as the most effective method of reducing
GVHD in clinical settings.524
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Background: cGVHD is a major cause of health problems and mor-
tality after allogeneic HCT. Routine clinical laboratory parameters
are established in outcomes monitoring of systemic inflammatory
or autoimmune disease, but their value in cGVHD is unknown.
To determine the relationship between laboratory markers of
Table 1. Correlation between laboratory parameters and categorical outcomes
Parameter (units) median, [range] CRP (mg/L) C3 (mg/dL) (mg/dL) IgG (mg/dL) HGB (g/dL) Lymph (K/uL) Platelets (K/uL)
Intensity of immunosuppression
none/mild (n549) 0.73 [0.3-44] 129 [66-179] 24 [15-37] 887 [200-3380] 13.3 [10.7-17.1] 1.63 [0.34-7.55] n.s.*
moderate (n571) 0.69 [0.15-41.6] 128 [64-210] 27 [13-61] 570 [98-2190] 12.5 [8.2-16.1] 1.22 [0.11-5.00] n.s.
high (n569) 1.22 [0.3-58.9] 147 [76-216] 31 [13-74] 580 [142-2050] 12.3 [8.9-16.2] 1.00 [0.15-5.30] n.s.
p-value 0.008 0.0046 0.0011 0.002 0.0006 0.011
Activity by therapeutic intent
non active (n584) 0.61 [0.15-44.3] 126 [64-210] 24 [13-74] n.s. n.s. n.s. 223 [33-465]
active (n571) 1.73 [0.3-58.9] 145 [76-216] 31 [15-68] n.s. n.s. n.s. 278 [56-648]
p-value <0.0001 0.0003 0.0004 0.012
NIH global severity stage
moderate (n562) 0.62 [0.15-27] 122 [66-187] n.s. n.s. n.s. n.s. 214 [33-461]
severe (n5125) 1.15 [0.26-58.9] 139 [64-216] n.s. n.s. n.s. n.s. 265 [34-648]
p-value <0.0001 0.0017 n.s. n.s. n.s. n.s. 0.0028
*Not significant.
Poster Session II S341inflammation and cGvHD severity and activity we analyzed a large
prospective patient cohort.
Methods: 189 adults were enrolled onto the NCI cross-sectional
cGvHD natural history study between 2004-2010. 33% had moder-
ate and 66% had severe cGvHD per NIH criteria (88% classic, 12%
overlap). 80% were receiving systemic immunosuppression and
failed a median of 4 (range 0-9) prior therapies (PST). Median fol-
low-up of survivors was 30.3 months (1-70). Laboratory predictors
included: CRP, ferritin, complement, albumin, IgG, b-2 microglo-
bulin, total protein, PTH (parathyroid hormone), ESR, CBC and
platelets. cGvHD severity outcomes included: NIH global stage
(moderate vs. severe), NIH average organ score, Lee symptom scale,
SF36 physical scale, Schirmer’s tear test, Schubert oral mucositis
scale (OMRS), skin body surface area (BSA) as continuous outcomes.
cGvHD activity outcomes (categorical) included: intensity of immu-
nosuppression (none/mild, moderate, high), clinician’s global assess-
ment (CGA) of change (7-point scale) and active vs. non active based
on therapeutic intent at enrollment.
Results: Correlation between continuous outcomes and laboratory
parameters was weak. Significant univariate analysis results related
to categorical outcomes are shown in the Table. By multivariable
logistic regression analysis taking into consideration clinical, demo-
graphic and laboratory parameters, lower albumin (p \ 0.0001),
higher platelets (p 5 0.045) and higher number of PST (p \
0.0001) were associated with active disease (identifying 75%of active
and 77% of non-active cases). Similarly, higher platelets (p5 0.021),
higher number of PST (p\ 0.0001) and lower FEV1 (p\ 0.0001)
were associated with severe disease (identifying 76% of severe and
74% of moderate cases). Only higher absolute lymphocytes (p 5
0.019), higher IgG (p5 0.0054) and lower PTH (p5 0.045) were as-
sociated with better survival in univariate analysis.
Conclusion: Some common laboratory indicators of inflammation
can serve as markers of active and severe cGvHD. Better understand-
ing of biologic mechanisms influencing these markers may lead to
deciphering the biology of cGVHD and designing therapeutic
approaches.525
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Introduction: Dendritic cells (DC) are centrally involved in the
development of acute graft-versus-host disease (GvHD) following
allogeneic hematopoietic cell transplantation (alloHCT). We pre-
viously showed that the activation status, as assessed by CMRF-44 antigen expression, of blood CD11c+ myeloid DC is highly
associated with the severity of acute GvHD, and that activated
DC may be detected in the circulation prior to clinical presentation
of GvHD (Transplantation 2007;83: 839–846). We also reported
that there was also a positive correlation between aGVHD and
the expression of the chemokine receptor CCR5 on myeloid DC
(Blood, 114,Suppl.:2251,2009). Because of the phenotypic and
functional heterogeneity of the CD11c+ DC population, we further
investigated the precise nature of the CD11c+ DC subset express-
ing CCR5 in the peripheral blood in 24 patients post alloHCT, and
correlated the findings with GVHD outcomes.
Methods: Peripheral blood was collected twice weekly up to day 100
post transplant from 24 alloHCT patients. The expression of CCR5
receptor on CD11c+ and CD11c- DC subsets was evaluated using
multiparameter flow cytometry.
Results: Eleven of 24 patients developed acute GvHD (4 grade I, 7
grades II-IV), the remaining 13 patients had no GvHD. The per-
centage of CD11c++ CD16+ DC expressing CCR5 correlated with
the development of acute GvHD grades II-IV. The maximum
CCR5 expression detected onCD11c+CD16+DC in patients devel-
oping grade II-IV GvHD (mean 36.0 +/2 6.9%, n 5 7)was higher
than in those with grade 0-I GvHD (17.2 +/2 3.2 %, n 5 17) (p 5
0.0153), and occurred prior to the clinical onset of GVHD in 6 of
8 patients with CCR5 levels . 20%. Levels of expression of CCR5
on other DC subsets, including CD16- CD11C+ DC, were not
preditive for GVHD.
Conclusion: Expression of CCR5 on circulating CD11c+ CD16+
myeloid DC post allo-HCT correlates with the development of
moderate to severe GvHD. This observation may indicate altered
homing patterns of these cells during the alloimuune response.
Detection of raised numbers of CCR5+ CD11c+ CD16+ DC could
allow earlier therapeutic intervention prior to the development of
clinical GVHD, if these findings are confirmed in a larger study.526
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Chronic GVHD (cGVHD) is a significant complication of alloge-
neic hematopoietic stem cell transplantation (AHSCT). Although T
cells have been implicated in cGVHD pathobiology, the role of the
thymus in this process has yet to be defined. We characterized
thymus and spleen T cell subsets in a murine model of cGVHD to
elucidate the role of the thymus in this process. The murine model
of minor-histocompatibility mismatch cGVHD, B10.D2- .
BALB/c, was validated by pathologic review that correlated with
the clinical scoring and showed cGVHDpathology in skin, stomach,
